Primary outcome: partial clinical response · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Secondary outcome: clinical flare · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Secondary outcome: CLASI · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Secondary outcome: Dermatology Quality of Life measure · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus
Oral chloroquine showed no clear difference in adverse events: severe compared with placebo (low certainty).
1 finding from 1 review
Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Secondary outcome: clinical flare · patients with cutaneous disease in systemic lupus erythematosus
Oral methotrexate showed no clear difference in secondary outcome: clinical flare compared with placebo (moderate certainty).
1 finding from 1 review
Secondary outcome: CLASI · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Secondary outcome: Dermatology Quality of Life measure · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus
Oral methotrexate showed no clear difference in adverse events: severe compared with placebo (moderate certainty).
1 finding from 1 review
Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus
Oral methotrexate showed no clear difference in adverse events: minor compared with placebo (moderate certainty).
1 finding from 1 review
Complete response · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Primary outcome: partial clinical response · patients with cutaneous disease in systemic lupus erythematosus
Oral hydroxychloroquine showed no clear difference in primary outcome: partial clinical response compared with placebo (low certainty).
1 finding from 1 review
Nausea · women undergoing regional anaesthesia for caesarean section
5‐HT3 antagonists may leads to lower nausea ‐ intraoperative compared with placebo (low certainty).
2 findings from 1 review
Vomiting ‐ intraoperative · women undergoing regional anaesthesia for caesarean section
It is very uncertain whether corticosteroids changes vomiting ‐ intraoperative compared with placebo (very low certainty).
1 finding from 1 review
Nausea · women undergoing regional anaesthesia for caesarean section
Corticosteroids probably leads to lower nausea ‐ postoperative compared with placebo (moderate certainty).
2 findings from 1 review
Vomiting ‐ postoperative · women undergoing regional anaesthesia for caesarean section
Corticosteroids may leads to lower vomiting ‐ postoperative compared with placebo (low certainty).
1 finding from 1 review
Nausea · preventing nausea and vomiting
It is very uncertain whether antihistamines changes nausea ‐ intraoperative compared with placebo (very low certainty).
2 findings from 1 review
Vomiting ‐ intraoperative · preventing nausea and vomiting
1 finding from 1 review
Vomiting ‐ postoperative · preventing nausea and vomiting
It is very uncertain whether antihistamines changes vomiting ‐ postoperative compared with placebo (very low certainty).
1 finding from 1 review